Monte Rosa Therapeutics GLUE Income Statement (2020-2026)

NASDAQ GLUE
$11.74 +0.03 (+0.26%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

Monte Rosa Therapeutics Quarterly Income Statement

Periods 25 quarters
Latest Jun 2026

Monte Rosa Therapeutics reported revenue of $8.97M and net income of -$43.40M for the quarter ended Jun 2026, down 61.3% year over year. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue
1.06M4.70M9.22M60.65M84.93M23.19M12.77M2.78M4.21M8.97M
Operating items
Research & DevelopmentR&D
15.12M18.13M17.91M20.94M21.34M24.87M26.75M29.08M28.31M27.14M27.03M28.05M27.62M38.87M32.19M30.65M36.68M41.98M44.07M47.96M
Selling, General & AdministrativeSG&A
4.75M5.26M6.39M6.29M7.02M7.62M7.50M8.14M8.66M7.73M8.98M9.28M8.13M8.78M8.70M8.10M9.06M10.52M10.18M10.13M
Other Operating ExpensesOther Opex
6.81M7.62M7.46M7.75M8.23M7.85M8.57M9.21M10.11M
Operating ExpensesOpex
19.87M23.39M24.30M27.23M28.36M32.49M34.26M37.22M36.97M34.86M36.01M37.34M35.74M47.64M40.89M38.75M45.74M52.50M54.24M58.10M
Operating IncomeOp. Inc
-19.87M-23.39M-24.30M-27.23M-28.36M-32.49M-34.26M-37.22M-36.97M-34.86M-34.95M-32.64M-26.53M13.00M44.04M-15.55M-32.98M-49.72M-50.03M-49.13M
EBIT
-19.87M-23.39M-24.30M-27.23M-28.36M-32.49M-34.26M-37.22M-36.97M-34.86M-34.95M-32.64M-26.53M13.00M44.04M-15.55M-32.98M-49.72M-50.03M-49.13M
Non-operating items
Non Operating Investment IncomeNon-Op. Investment Inc.
0.12M-0.02M-0.13M0.02M0.06M
Other Non Operating IncomeOther Non Op Inc.
0.02M-0.07M0.10M0.13M0.06M-0.28M-0.09M-0.09M0.03M-0.78M0.62M-0.05M-0.15M0.00M0.17M1.39M-0.03M-0.05M-0.01M0.03M
Non Operating IncomeNon Op. Inc.
0.03M-0.05M0.37M0.76M1.04M1.71M2.22M2.23M2.25M1.59M3.06M2.58M2.74M2.60M3.67M4.46M2.72M3.64M5.58M5.94M
Net income details
EBT
-19.87M-23.39M-24.30M-26.47M-27.32M-30.78M-32.04M-34.99M-34.71M-33.27M-31.89M-30.06M-23.79M15.60M47.71M-11.10M-30.26M-46.08M-44.45M-43.19M
Tax ProvisionsTaxes
0.19M0.17M-0.02M0.10M0.25M0.07M2.16M0.82M1.20M-3.18M0.06M0.10M0.21M
Profit After TaxPAT
-19.87M-23.39M-24.30M-26.47M-27.32M-30.78M-32.04M-35.18M-34.88M-33.25M-31.98M-30.31M-23.86M13.44M46.88M-12.29M-27.08M-46.13M-44.55M-43.40M
Income from Continuing OperationsIncome (Continuing)
-19.87M-23.39M-24.30M-26.47M-27.32M-30.78M-32.04M-35.18M-34.88M-33.25M-31.98M-30.31M-23.86M13.44M46.88M-12.29M-27.08M-46.13M-44.55M-43.40M
Consolidated Net IncomeConsol Net Inc.
-19.87M-23.39M-24.30M-26.47M-27.32M-30.78M-32.04M-35.18M-34.88M-33.25M-31.98M-30.31M-23.86M13.44M46.88M-12.29M-27.08M-46.13M-44.55M-43.40M
Income towards Parent CompanyParent Net Inc
-19.84M-23.48M-23.93M-26.47M-27.32M-30.78M-32.04M-35.18M-34.88M-33.30M-31.97M-30.31M-23.86M13.44M46.88M-12.29M-27.08M-46.11M-44.50M-43.40M
Net Income towards Common StockholdersNet Income
-19.84M-23.48M-23.93M-26.47M-27.32M-30.78M-32.04M-35.18M-34.88M-33.30M-31.97M-30.31M-23.86M13.44M46.88M-12.29M-27.08M-46.11M-44.50M-43.40M
Additional items
EPS (Basic)
-0.43-0.94-0.51-0.57-0.58-0.65-0.65-0.71-0.70-0.65-0.53-0.43-0.290.180.57-0.15-0.33-0.56-0.45-0.43
EPS (Diluted)
-0.43-0.94-0.51-0.57-0.58-0.65-0.65-0.71-0.70-0.65-0.53-0.43-0.290.180.57-0.15-0.33-0.56-0.45-0.43
Shares Outstanding
45.99M25.00M46.60M46.67M46.73M47.23M49.35M49.43M49.81M51.40M60.16M71.23M82.01M73.91M82.15M82.19M82.40M83.07M99.88M101.48M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
45.99M25.00M46.60M46.67M46.73M47.23M49.35M49.43M49.81M51.40M60.16M71.23M82.01M73.91M82.96M82.19M82.40M83.07M99.88M101.48M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
46.48M25.00M46.63M46.68M48.37M49.32M49.36M49.59M50.07M50.14M50.20M61.33M82.01M61.51M82.15M82.19M82.40M83.07M84.32M85.23M
EBITDA
-19.27M-22.58M-23.50M-26.34M-27.33M-31.42M-33.06M-35.83M-35.13M-33.02M-33.05M-30.58M-24.42M15.06M46.08M-13.43M-30.88M-47.58M-48.01M-47.22M
Tax Rate
13.87%1.72%

Monte Rosa Therapeutics Income Statement API

Pull Monte Rosa Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=GLUE&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY